Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2397-768X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers ; volume:6 ; number:1 ; day:19 ; month:7 ; year:2022 ; pages:1-12 ; date:12.2022
npj precision oncology ; 6, Heft 1 (19.7.2022), 1-12, 12.2022
- Urheber
-
Alblihy, Adel
Ali, Reem
Algethami, Mashael
Shoqafi, Ahmed
Toss, Michael S.
Brownlie, Juliette
Tatum, Natalie J.
Hickson, Ian
Moran, Paloma Ordonez
Grabowska, Anna
Jeyapalan, Jennie N.
Mongan, Nigel P.
Rakha, Emad A.
Madhusudan, Srinivasan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41698-022-00298-0
- URN
-
urn:nbn:de:101:1-2022100122405405616539
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Alblihy, Adel
- Ali, Reem
- Algethami, Mashael
- Shoqafi, Ahmed
- Toss, Michael S.
- Brownlie, Juliette
- Tatum, Natalie J.
- Hickson, Ian
- Moran, Paloma Ordonez
- Grabowska, Anna
- Jeyapalan, Jennie N.
- Mongan, Nigel P.
- Rakha, Emad A.
- Madhusudan, Srinivasan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma
Combination immunotherapy overcomes resistance in MHC class I-deficient cancer
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells
Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers
Modeling synthetic lethality
Embryonic viability, lipase deficiency, hypertriglyceridemia and neonatal lethality in a novel LMF1-deficient mouse model
Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma
Combination immunotherapy overcomes resistance in MHC class I-deficient cancer
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells
Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers
Modeling synthetic lethality
Embryonic viability, lipase deficiency, hypertriglyceridemia and neonatal lethality in a novel LMF1-deficient mouse model
Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma
Combination immunotherapy overcomes resistance in MHC class I-deficient cancer
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells
Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers
Modeling synthetic lethality